The vision for X Games' future under new CEO Jeremy Bloom includes sports betting, AI judging, fantasy sports and the debut ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...

The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan ™ interferometer, which provides PEAK spectral resolution. The precise linear ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day. Vertex (VRTX) has received quite a bit of attention from Zacks.com ...

Attentive.ai, a leading AI-based SaaS startup, today announced the successful close of its Series A2 funding round, ...

Long a trendsetter in action sports, the X Games and its new CEO ... Using Google Cloud tools including Vertex AI, Bloom thinks this experiment has potential to change the game on halfpipes ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Vertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks Internet Software industry and the S&P 500’s return of 38.1%, 40.3% and 26.8 ...